<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308278</url>
  </required_header>
  <id_info>
    <org_study_id>LLB-2019-03</org_study_id>
    <nct_id>NCT04308278</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection</brief_title>
  <acronym>EBVAST</acronym>
  <official_title>Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Labo'Life</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Labo'Life</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Worldwide, 95% of adults are infected with Epstein-Barr Virus (EBV). These infections may
      cause different diseases. In most cases, EBV infection is asymptomatic because of a highly
      effective host immune response. Some individuals develop infectious mononucleosis (a
      self-limiting lymphoproliferative disorder in adolescents and young adults that is considered
      to be the primary infection), while others develop chronic fatigue syndrome, EBV-associated
      lymphoid, or epithelial malignancies.

      Today, there is no available treatment to treat and destroy EBV. The treatment is essentially
      symptomatic (treatment of the symptoms and not of the virus itself) with analgesics for pain
      for example.

      The studied drugs are 2LEBV® and 2LXFS®, from Labo'Life company, and the treatment schema is
      the same for the two drugs: it consists in taking the content of one capsule per day,
      sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is
      taken, capsule 1 of the next blister should be taken on the next day to continue the
      treatment.

      The duration of treatment will be of 6 months of continuous intake of the content of 1
      capsule/day.

      The aim of this study is to provide additional information on effectiveness on the 2LEBV® and
      2LXFS®in the treatment of EBV chronic and acute infections, and in particular to demonstrate
      their effectiveness versus placebo in the reduction of asthenia and other symptoms in EBV
      infection.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the general fatigue scale of the Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire at the end of the treatment.</measure>
    <time_frame>6 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on physical fatigue, reduced activity, reduced motivation and mental fatigue scales on the MFI-20 questionnaire between the 2LEBV® or the 2LXFS®/2LEBV® group versus the placebo group</measure>
    <time_frame>6 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.
Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>3 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the efficacy of the treatment on general fatigue and other dimensions of the MFI-20 questionnaire between the 2LEBV® and the 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
    <description>Multidiensional Fatigue Inventory-20 (MFI-20) questionnaire. 5 scales. Higher scores means worse outcome.
General Fatigue dimension: Minimum value: 4. Maximum Value: 20. Physical fatigue dimension: Minimum value: 4. Maximum Value: 20. Reduced activity dimension: Minimum value: 4. Maximum Value: 20. Reduced motivation dimension: Minimum value: 4. Maximum Value: 20. Mental fatigue dimension: Minimum value: 4. Maximum Value: 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the evolution of the lymphocytes typing between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparisons of the efficacy of the treatment on others symptoms related to EBV infection and their duration between the 2LEBV® and 2LXFS®/2LEBV® group versus the placebo group.</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>EBV Infection</condition>
  <arm_group>
    <arm_group_label>2LEBV® / 2LXFS®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 months of treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2LEBV® / 2LXFS®</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>2LEBV® / 2LXFS®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Pré-Inclusion Criteria:

          -  Patients, male or female, aged 12 years and older,

          -  Patient with fatigue for 1 month or more,

          -  Patient with at least two other symptoms among the following: Long-lasting exhaustion
             even after light exertion, subfebrile state, fever, loss of appetite, nausea, angina,
             conjunctivis, sensitive cervical or axillary lymph nodes, erythematous and swollen
             tonsil, headaches, sore throat, myalgia, muscular weakness, arthralgia, splenomegaly,
             visual disorders, memory disorders, attention deficit disorders, sleep disorders,
             gastrointestinal disorders, breathing disorders, cardiovascular disorders.

          -  Patient (and/or parents if necessary) agrees to perform serology for the study,

          -  Patient (and/or parents if necessary) agrees to perform lymphocyte typing for the
             study during the pre-inclusion visit,

          -  Patients (and/or parents if necessary) having the faculties to understand and respect
             the constraints of the study,

          -  Signature of the Informed Consent Form by the patient (and/or parents if necessary).

        Inclusion Criteria:

        - Patient who have a positive serology for EBV (IgG and/or IgM positive).

        Exclusion Criteria:

          -  Patient who have received any treatment with the 2LEBV® or 2LXFS®,

          -  Patients who have received any homeopathic treatment in the previous 2 months prior to
             the study,

          -  Patients under immunosuppressive treatment,

          -  Patient undergoing treatment for psychiatric disorders,

          -  Patients having received immunotherapy or micro-immunotherapy during the last 3
             months,

          -  Patients with known lactose intolerance,

          -  Pregnant or breastfeeding women,

          -  Patients who participated in a clinical study in the previous 2-months period,

          -  Patients (and/or parents of patients if necessary) who are not sufficiently motivated
             to engage on the total study follow-up period, or likely to travel or to move before
             the end of the study,

          -  Patients with severe immunodeficiency disease requiring long term treatment (*) or
             patients under chemotherapy or radiotherapy,

          -  Patients under homeopathic or phytotherapy treatment,

          -  Patients addicted to or using recreational drugs,

          -  Patient under guardianship and/or curatorship, (*) important renal or respiratory
             insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Léa FERRAND</last_name>
    <phone>6 42 62 43 72</phone>
    <phone_ext>+33</phone_ext>
    <email>lea.ferrand@labolife.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Astrid GARREAU</last_name>
    <phone>6 59 11 39 29</phone>
    <phone_ext>+33</phone_ext>
    <email>astrid.garreau@labolife.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Aartselaar</city>
        <zip>2630</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Ilse BUNTINX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Ilse BUNTINX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Boortmeerbeek</city>
        <zip>3190</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria-Magdalena HAEMELS, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Maria-Magdalena HAEMELS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Jan-Jaap HUYSMAN, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Jan-Jaap HUYSMAN, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Maarteen AVET, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Maarteen AVET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Jette</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Quirico BLONDA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Quirico BLONDA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Limal</city>
        <zip>1300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Quirico BLONDA, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Quirico BLONDA, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private Practice</name>
      <address>
        <city>Nivelles</city>
        <zip>1400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Véronique BAUDOUX, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Véronique BAUDOUX, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Private practice</name>
      <address>
        <city>Waregem</city>
        <zip>8790</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <last_name>Thijs LONCKE, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Thijs LONCKE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 11, 2020</study_first_submitted>
  <study_first_submitted_qc>March 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2020</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Epstein-Barr Virus Infections</mesh_term>
    <mesh_term>Asthenia</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

